Abstract: Provided is a medicament or a method for treating or preventing a corneal endothelial condition, disorder or disease due to a transforming growth factor-? (TGF-?) signal in corneal endothelial cells using a p38 MAP kinase inhibitor (in particular AKP-001), such as a pyrimidinyl isoxazole derivative or a pyridyl isoxazole derivative. In a preferred embodiment, the corneal endothelial condition, disorder or disease due to the TGF-? signal is Fuchs' corneal endothelial dystrophy.

Abstract: There are provided a resin composition that is suitable for the production of a flame-retardant molded article and that can provide high flame retardancy even with a small amount of flame retardant added, and a flame retardancy determination method for determining the flame retardancy of a resin composition. The resin composition of the present invention contains a thermoplastic resin, a cellulosic material, and a phosphate flame retardant and satisfies relational expressions (1) and (2) (where in expressions (1) and (2), TP, TB, and TCMP are temperatures at weight loss rate peaks in thermogravimetric analysis, TP is a temperature (° C.) at a weight loss rate peak of the thermoplastic resin, TB is a temperature (° C.) at a weight loss rate peak of the cellulosic material, and TCMP is a temperature (° C.) at a weight loss rate peak of the resin composition. When the resin composition has two weight loss rate peaks, TCMP is a temperature at a peak on a lower temperature side).

Abstract: Provided are a morbidity diagnosis support system, a morbidity diagnosis data-generating system, and a morbidity diagnosis support method that are capable of supporting a highly reliable morbidity diagnosis. A morbidity diagnosis support system includes an extension device for extending a tissue section of cells, an image-photographing device for acquiring image data by image-photographing the tissue section, an image analysis device for analyzing the image data to calculate an index of morbidity based on a mode of cracks generated in the tissue section by the extension, and an output device for outputting the calculated index.

Abstract: Provided is an agent for treating or preventing a corneal endothelial disorder wherein cell proliferation is required. More specifically, provided is an agent for treating or preventing a corneal endothelial disorder, wherein cell proliferation is required, said agent comprising a p38MAP kinase inhibitor. In a preferred embodiment, the corneal endothelial disorder is a wound. In a preferred embodiment, the p38MAP kinase inhibitor is soluble in water. The p38MAP kinase inhibitor may comprise 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580) or a salt thereof.

Abstract: A platinum core-shell catalyst that uses palladium (Pd) as a core metal, or a platinum catalyst containing platinum and a metal besides platinum is manufactured industrially on a mass scale. The platinum catalyst is supported on carbon and has excellent oxygen reduction activity. The platinum catalyst is made for a fuel cell by bringing about the presence of a chemical species imparting higher potential than the initial oxide formation potential of the platinum of the platinum catalyst, and by bringing about the presence of a chemical species imparting lower potential than the initial oxide formation potential of the platinum of the platinum catalyst. The manufacture is carried out in a dispersion solution of the platinum catalyst dispersed in an acidic solution containing protons.

Abstract: An ion analyzer that generates product ions from precursor ions derived from a sample component and analyzes the product ions includes a reaction chamber (2) into which the precursor ion is introduced, a radical generation chamber (51), a material gas supply source (52) configured to introduce material gas into the radical generation chamber (51), a vacuum evacuator (57) configured to evacuate the radical generation chamber (51), a vacuum discharge unit (53) configured to generate a vacuum discharge in the radical generation chamber (51), a radical irradiation unit (54) configured to irradiate an inside of the reaction chamber (2) with radicals generated from the material gas in the radical generation chamber (51), and a separation and detection (3) configured to separate and detect product ions generated from the precursor ion by reaction with the radicals according to at least one of a mass-to-charge ratio and ion mobility.

Abstract: A magnetic fluid drive unit 100 having a double tube 10 comprising an inner tube 11 and an outer tube 12 formed on the outer side of the inner tube 11, and a magnetic field applicator 30 installed on the outer side of the double tube 10, the inner tube 11 having, in the region where a magnetic field is applied by the magnetic field applicator 30, a high heat conducting region 21 and a low heat conducting region 22 aligned in the lengthwise direction of the inner tube 11, the inside of the inner tube 11 being a heating medium flow path, and the area between the inner tube 11 and the outer tube 12 being a magnetic fluid flow path.

Abstract: Provided is a transformer oil that has high environmental compatibility and is expected to be further improved in transformer cooling properties. The transformer oil is a transformer oil prepared by mixing a plant oil and a silicone oil and containing no mineral oil, in which a volume ratio of the plant oil to the silicone oil is 3:7 to 7:3 and magnetic particles (for example, temperature-sensitive magnetic particles) are dispersed.

Abstract: A liquid-crystal varifocal lens includes a liquid crystal lens, and an ultrasonic transducer for generating an ultrasonic wave with a frequency that matches a resonant frequency of the liquid crystal lens. The ultrasonic transducer generates flexural oscillation in the liquid crystal lens such that the flexural oscillation has a vibration intensity decreasing continuously from the center to the circumference of a liquid crystal layer, whereby the thickness of the liquid crystal layer is changed, with the result that the orientation of the liquid crystal molecules is changed.

Abstract: An analytical device includes: a reaction unit into which an ion derived from a sample component is introduced; a radical generation unit that generates a radical by vacuum discharge and comprises a raw material introduction chamber into which a plasma raw material is introduced; a connection part that introduces the radical generated in the radical generation unit into a vacuum chamber, the vacuum chamber having a pressure lower than a pressure of the raw material introduction chamber and being connected to the reaction unit; and a separation unit that separates a generated ion generated by a reaction with the radical introduced via the connection part into the reaction unit according to m/z and/or ion mobility, wherein an inner diameter of a cross section of the connection part is equal to or less than 20 millimeters.

Abstract: An exhaust gas control apparatus for an internal combustion engine is provided. The exhaust gas control apparatus is equipped with a NOx reduction catalyst, a reducing agent tank, a reducing agent supply device, a booster, a heater, and an electronic control unit. The electronic control unit is configured to perform control of raising a temperature of a reducing agent to a first target temperature such that the reducing agent supplied by the reducing agent supply device is brought into a gas-liquid mixed state in an exhaust passage, when energy of exhaust gas is lower than a first threshold.

Abstract: Relatively inexpensive and practical cell deterioration diagnostic method and cell deterioration diagnostic device are provided. A cell deterioration diagnostic method diagnoses cell deterioration of a secondary cell having a transient characteristic. The method includes: a charging step of charging the secondary cell; a calculation step of calculating an integrated value of a potential difference obtained by subtracting a cell internal voltage V0 of the secondary cell from a cell inter-terminal voltage of the secondary cell by integrating the potential difference as the cell inter-terminal voltage converges to the cell internal voltage V0 after completion of charging; and a diagnosis step of diagnosing the cell deterioration of the secondary cell based on the integrated value.

Abstract: Provided are a morbidity diagnosis support system, a morbidity diagnosis data-generating system, and a morbidity diagnosis support method that are capable of supporting a highly reliable morbidity diagnosis. A morbidity diagnosis support system includes an extension device for extending a tissue section of cells, an image-photographing device for acquiring image data by image-photographing the tissue section, an image analysis device for analyzing the image data to calculate an index of morbidity based on a mode of cracks generated in the tissue section by the extension, and an output device for outputting the calculated index.

Abstract: [Problem] To provide, in order to manufacture cells to transplant into patients with corneal endothelial failure, a medium used to culture corneal endothelial cells obtained from human corneal tissue and grow said cells while maintaining the morphology thereof as corneal endothelial cells. [Solution] A medium containing a conditioned medium from mesenchymal stem cells; and a method in which said medium is used to culture corneal endothelial cells.

Abstract: Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-? (TGF-?) signals, mitochondrial abnormalities, and/or endoplasmic reticulum (ER) associated stress in corneal endothelial cells, using p38 MAP kinase inhibitors. The present invention provides a drug which includes p38 MAP kinase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-? signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.

Abstract: Provided are a liquid crystal molecule orientation control method and a liquid crystal device which render it possible to change the orientation of liquid crystal molecules without using an electric field. In controlling the orientation of liquid crystal molecules 103a, which are contained in a liquid crystal material 103 sandwiched between alignment films 104, by the liquid crystal molecule orientation control method, an ultrasonic wave is generated in a piezoelectric material 102 so as to propagate to the liquid crystal material 103, and static pressure is generated in accordance with the ultrasonic wave, with the result that the orientation is changed in accordance with the magnitude of the static pressure.

Abstract: A liquid-crystal varifocal lens includes a liquid crystal lens, and an ultrasonic transducer for generating an ultrasonic wave with a frequency that matches a resonant frequency of the liquid crystal lens. The ultrasonic transducer generates flexural oscillation in the liquid crystal lens such that the flexural oscillation has a vibration intensity decreasing continuously from the center to the circumference of a liquid crystal layer, whereby the thickness of the liquid crystal layer is changed, with the result that the orientation of the liquid crystal molecules is changed.

Abstract: An exhaust gas control apparatus for an internal combustion engine is provided. The exhaust gas control apparatus is equipped with a NOx reduction catalyst, a reducing agent tank, a reducing agent supply device, a booster, a heater, and an electronic control unit. The electronic control unit is configured to perform control of raising a temperature of a reducing agent to a first target temperature such that the reducing agent supplied by the reducing agent supply device is brought into a gas-liquid mixed state in an exhaust passage, when energy of exhaust gas is lower than a first threshold.

Abstract: A magnetic fluid drive unit 100 having a double tube 10 comprising an inner tube 11 and an outer tube 12 formed on the outer side of the inner tube 11, and a magnetic field applicator 30 installed on the outer side of the double tube 10, the inner tube 11 having, in the region where a magnetic field is applied by the magnetic field applicator 30, a high heat conducting region 21 and a low heat conducting region 22 aligned in the lengthwise direction of the inner tube 11, the inside of the inner tube 11 being a heating medium flow path, and the area between the inner tube 11 and the outer tube 12 being a magnetic fluid flow path.

Abstract: A tau aggregation inhibitor can sufficiently inhibit a tau protein from aggregating in cells. The inhibitor includes a 4-substituted catechol structure compound, having, at position 4 of its catechol ring, an electron-donating substituent R other than a hydrocarbon group, or a salt thereof. The 4-substituted catechol structure compound is preferably 4-aminocatechol or 1,2,4-benzenetriol. Examples of tauopathies to which this inhibitor is applicable include AD, Down's syndrome, frontotemporal dementia, cotricobasal degeneration (CBD) and progressive supranuclear palsy (PSP).